• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

This week in optometry: October 30-November 3


Catch up on what happened in optometry during the week of October 30-November 3.

Catch up with what Optometry Times®' shared this week:

What are microplastics and why should we care?

Katherine M. Mastrota, MS, OD, FAAO, Dipl ABO

Microplastics—omnipresent, indigestible, inhalable, and nonbiodegradable—can be found in the air we breathe and the foods we consume. There is possible evidence that these assumed microplastics particles can pollute human serum.1

Microplastics and nanoplastics are key indicators of the plasticine era, widely spread across different ecosystems. Microplastics and nanoplastics become global stressors because of their inherent physicochemical characteristics and potential impact on natural ecosystems and humans.

Learn more...

The future of telehealth in primary eye care

Thomas A. Wong, OD, FAAO, FNAP

The increased use of technology such as medical imaging, artificial intelligence, and patient communication tools provides opportunities for private practices, universities, community health centers, management centers, and other optometric clinics to collaborate and provide quality care by working with other health care professionals in a changing world. This article will discuss how telehealth can improve access to high-quality vision care and most directly benefit our patients.1

Read on...

Phase 3 OAKS and DERBY studies show clinically meaningful reduction in GA lesion growth

Sydney M Crago, Editor, Modern Retina

Results from the phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (SYFOVRE) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were published in The Lancet. The results note that the 24-month results saw clinically meaningful reduction of GA lesion growth with increasing effects over time in both every-other-month and monthly injections. The results also noted a well-demonstrated safety profile in a broad population of more than 1,200 patients.1

More here...

Charting the path to optimal eye emergency care at CRU 2023

Steven A. Greenstein, MD; Sheryl Stevenson, Eye Care Group Editorial Director; Kassi Jackson, Editor

Set against the backdrop of California’s Napa Valley, the second annual Current, Relevant, Useful (CRU) Eye Symposium will take place at the Silverado Resort and Spa from November 10 to 12, 2023.

Clinicians from the eye care field will delve into various subjects, including anterior segment disease, glaucoma, retina, advanced contact lenses, and myopia management. S. Barry Eiden, OD, FAAO, FSLS; Stephanie Woo, OD, FAAO, FSLS; John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and Laura Periman, MD, are the cochairs of the meeting, with honorary ambassador Vance Thompson, MD, FACS.

Steven A. Greenstein, MD, who is part of the faculty for the CRU Eye Symposium, recently spoke with Sheryl Stevenson, Eye Care Group editorial director, to highlight his presentation.

See more...

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
© 2024 MJH Life Sciences

All rights reserved.